Current Partners Include:
AC Immune SA is a Swiss-based biopharmaceutical company and a leader in Alzheimer’s disease drug development. AC Immune develops innovative therapeutics with “best in class” potential against Alzheimer’s disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. Learn more.
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2012, the Group employed 110,000 people and had sales of €39.7 billion. Capital expenditures amounted to €1.9 billion, R&D expenses to €3.0 billion. Learn more.
Ci-Co Healthcare, based in Seoul, Korea, was established in 1993. For the past 20 years Ci-Co Healthcare has partnered with the laboratory medicine departments of more than 300 hospitals across the country, supplying them with in-vitro diagnosis devices, including immunology and biochemistry, on-site emergency inspection systems, and Siemens laboratory automation systems. Learn more.
Curium is a world-class nuclear medicine solutions provider with more than a century of industry experience. Formed by the union of IBA Molecular and Mallinckrodt Nuclear Medicine LLC, Curium is the largest vertically integrated radiopharmaceutical product manufacturer in the industry. With manufacturing facilities across Europe and the United States, Curium supports over 14 million patients around the world with SPECT, PET, and therapeutic radiopharmaceuticals to provide potentially life-saving diagnostic solutions. The Curium brand name is inspired by the work of radiation researchers Marie and Pierre Curie and emphasizes a focus on nuclear medicine. Learn more.
Cyclotek Ltd is the largest commercial PET radiopharmaceutical manufacturer in Australia and New Zealand. The Cyclotek group has many years of experience in the production of FDG and investigational medicinal products (IMPs) for both international pharmaceutical companies and investigator sponsored clinical trials. Learn more.
DuChemBio Co., Ltd., established in 2002, is a leading company operating the largest radiopharmacy network (8 cyclotrons) in Korea, and is currently installing a cyclotron center in Manila, Philippines to supply a variety of radiopharmaceuticals. Having the confidence that “the true meaning of healthcare corresponds with early diagnosis as well as timely treatment based on early and accurate diagnosis,” DuChemBio continues to focus on diagnosis-related businesses with the acquisition of an in-vitro diagnosis distribution company in Korea in April 2012, and with the plan to expand its business to East Asian markets as a company specialized in radiopharmaceuticals. Learn more.
ISOLOGIC Innovative Radiopharmaceuticals (ISOLOGIC) is a Canadian radiopharmaceutical company dedicated to nuclear medicine and the science of radiopharmaceutical production. ISOLOGIC’s commitment to these fields includes cyclotron centers, SPECT and PET radiopharmaceutical manufacturing facilities throughout Canada. Utilizing significant experience, expertise to provide its customers and patients with reliable, safe and high quality radiopharmaceutical products and services. ISOLOGIC’s open formulary of radiopharmaceutical drugs and medical devices provides the flexibility of choice, providing its customers with access to all radiopharmaceuticals, having Health Canada market authorization. Learn more.
PET Pharm Biotech Co., Ltd. was incorporated in 2011 with its head office and manufacturing site in Taipei, Taiwan. As a premium producer of PET drugs for clinical use, PET Pharm Biotech is focusing on commercialization of newly developed PET tracers and other radiopharmaceuticals for the benefit of Taiwan’s 23 million people. It is a partner for international developers to introduce their innovative radiopharmaceuticals into Taiwan and other regional markets. Learn more.
PositronPharma SA was founded in 2010 and is the leading provider of PET radiopharmaceuticals in Chile. By introducing cutting-edge technology and new radiopharmaceuticals PositronPharma aims to support PET centers, physicians and their patients with best-in-class products allowing for early detection, characterization and treatment of life threatening diseases. As part of this commitment PositronPharma also supports different clinical trials and investigator sponsored studies in the field of oncology and neurodegenerative disorders. Learn more.
The early vision for molecular imaging was to revolutionize clinical diagnostics and therapeutics to better understand and treat the biology of disease. Today, SOFIE brings that vision to life by increasing the adoption and application diversity of theranostics by removing the cost and complexity traditionally associated with the technology. With a full line of imaging and radiochemistry systems and a premier radiopharmacy network and contract manufacturing organization to supply novel agents for diagnosis and therapy, SOFIE is dedicated to improving patient health. Learn more.
SWAN-Isotopen AG is a spin-off company of the University Hospital of Bern, Inselspital, producing full GMP radiopharmaceuticals. The SWAN production site also hosts multidisciplinary research teams of high energy physicists and radiochemists from the University of Bern. Learn more.